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Background: Atherosclerosis (AT) is a chronic inflammatory disease characterized by the accumulation of
inflammatory cells, lipoproteins and fibrous tissue in the walls of arteries. AT is the primary cause of heart attacks
and stroke and is the leading cause of death in Western countries. To date, the pathogenesis of AT is not
well-defined. Studies have shown that the dedifferentiation of contractile and quiescent vascular smooth muscle
cells (SMC) to the proliferative, migratory and synthetic phenotype in the intima is pivotal for the onset and
progression of AT. To further delineate the mechanisms underlying the pathogenesis of AT, we analyzed the early
molecular pathways and networks involved in the SMC phenotype transformation.
Methods: Quiescent human coronary artery SMCs were treated with minimally-oxidized LDL (moxLDL), for 3 hours
and 21 hours, respectively. Transcriptomic data was generated for both time-points using microarrays and was
subjected to pathway analysis using Gene Set Enrichment Analysis, GeneMANIA and Ingenuity software tools. Gene
expression heat maps and pathways enriched in differentially expressed genes were compared to identify
functional biological themes to elucidate early and late molecular mechanisms of moxLDL-induced SMC
dedifferentiation.
Results: Differentially expressed genes were found to be enriched in cholesterol biosynthesis, inflammatory
cytokines, chemokines, growth factors, cell cycle control and myogenic contraction themes. These pathways are
consistent with inflammatory responses, cell proliferation, migration and ECM production, which are characteristic
of SMC dedifferentiation. Furthermore, up-regulation of cholesterol synthesis and dysregulation of cholesterol
metabolism was observed in moxLDL-induced SMC. These observations are consistent with the accumulation of
cholesterol and oxidized cholesterol esters, which induce proinflammatory reactions during atherogenesis. Our data
implicate for the first time IL12, IFN-α, HGF, CSF3, and VEGF signaling in SMC phenotype transformation. GPCR
signaling, HBP1 (repressor of cyclin D1 and CDKN1B), and ID2 and ZEB1 transcriptional regulators were also found
to have important roles in SMC dedifferentiation. Several microRNAs were observed to regulate the SMC phenotype
transformation via an interaction with IFN-γ pathway. Also, several “nexus” genes in complex networks, including
components of the multi-subunit enzyme complex involved in the terminal stages of cholesterol synthesis,
microRNAs (miR-203, miR-511, miR-590-3p, miR-346*/miR- 1207-5p/miR-4763-3p), GPCR proteins (GPR1, GPR64,
GPRC5A, GPR171, GPR176, GPR32, GPR25, GPR124) and signal transduction pathways, were found to be regulated.
Conclusions: The systems biology analysis of the in vitro model of moxLDL-induced VSMC phenotype
transformation was associated with the regulation of several genes not previously implicated in SMC phenotype
transformation. The identification of these potential candidate genes enable hypothesis generation and in vivo
functional experimentation (such as gain and loss-of-function studies) to establish causality with the process of SMC
phenotype transformation and atherogenesis.* Correspondence: joe.minta@gmail.com
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Atherosclerosis (AT) is a chronic inflammatory disease
of medium and large arteries characterized by the accu-
mulation of inflammatory cells, lipoproteins and fibrous
tissue that lead to the formation of atherosclerotic pla-
ques. It is the primary cause of heart attacks and stroke,
and the leading cause of death and disability in devel-
oped countries [1-3]. AT is a multifactorial disease with
genetic, environmental and lifestyle risk factors. A var-
iety of atherogenic stimuli including hemodynamic shear
stress, infections, lipids and proinflammatory cytokines
induce endothelial cell dysfunction and permit the mi-
gration of mononuclear cells into the subendothelial
space. This process is associated with the transformation
of quiescent contractile smooth muscle cells (SMCs) to
a proliferative and migratory phenotype. As a result of
this transformation, SMCs migrate to the neointima
where they produce an extracellular matrix that stabi-
lizes the atherosclerotic plaque [4-9]. Lipids deposited in
atherosclerotic plaques are derived largely from the
lower-density lipoproteins [LDL, LDL-1, VLDL, beta-
VLDL, and Lp(a)] of the blood [10,11]. 12/15- lipoxygenase
and myeloperoxidase have been identified as lipid-
oxidizing enzymes that are involved in the formation
of biologically active oxidized lipids (cholesterol ester
hydroperoxides). The accumulation of these oxidized
lipids may initiate the proinflammatory activation of
macrophages and SMCs in atherosclerotic lesions
[12,13]. Mildly or minimally oxidized forms of LDL
(moxLDL) activate both cell-mediated and humoral
immune responses that perpetuate the chronic inflam-
matory reactions characteristic of atherosclerosis. The
accumulation of cholesterol esters in macrophages
and macrophage-like cells induce the release of pro-
inflammatory cytokines, chemokines, reactive oxygen
radicals, and matrix metalloproteinases [14-16].
Although the majority of foam cells, containing oxi-
dized lipoproteins, in atherosclerotic lesions are derived
from macrophages, SMCs also give rise to a significant
number of lipid laden cells. SMCs exposed to athero-
genic stimuli such as inflammatory cytokines, shear
stress, moxLDL or reactive oxygen radicals or lipids
[6,17-19] express high levels of a variety of lipid-binding
membrane receptors including LDLR, VLDLR, LOX-1,
CD36, type I and type II scavenger receptors, and
CXCL16/SR-PSOX for cholesterol uptake [20]. Athero-
genic cytokines such as IL-1α, TNF-α, and MCSF further
upregulate the expression of LDLR and VLDLR [21].
The binding of moxLDL to these receptors then results
in the accumulation of high levels of cholesterol and
cholesteryl esters by the macrophages and SMCs, which
then transform into foam cells in early fatty streak
lesions. These changes characterize the initiation and
progression of atherosclerosis and restenosis [19].moxLDL has been shown to induce SMC transform-
ation from the “contractile” phenotype to the “migratory,
proliferative and synthetic” phenotype, central to intimal
hyperplasia and atherogenesis [4,19]. Activated SMCs
also produce cytokines such as PDGF, TGF-β and IFN,
which contribute to the initiation and propagation of the
inflammatory response of the vessel wall [18,19,22,23].
Recently, a number of investigators have used system-
atic approaches to investigate atherosclerosis. In these
works, biopsies of stable and unstable plaques from
symptomatic and asymptomatic patients as well as
lesions in mouse models for AT have been examined.
Gene expression profiles, pathways and molecular net-
works were analyzed, that underlie the formation of ath-
erosclerotic plaques [24-31]. As a result, these studies
have implicated many potential human atherogenic
genes related to lipid homeostasis and have reported
changes in the cytokine-induced immune and inflamma-
tory responses as part of the pathogenesis of AT. Such
studies have also underscored SMC dedifferentiation as
a key process in the initiation and progression of AT.
Despite these advances, the molecular mechanisms of
SMC transformation during initiation and progression of
atherogenesis are not well-defined. However, the identifi-
cation of early critical pathways involved in SMC trans-
formation can provide insights into the mechanisms that
underlie the pathogenesis of AT and cardiovascular dis-
eases and could deliver potential targets for drug discov-
ery. To facilitate such analyses, we have previously used
oligonucleotide microarrays to analyze the genome-wide
differential gene expression in quiescent primary human
coronary artery SMCs induced with moxLDL for 3h and
21h [32]. This work uncovered several genes not previ-
ously implicated in the moxLDL-induced SMC pheno-
type transformation and described numerous functional
categories of genes with altered gene expression.
Here, we significantly extended the original analysis of
the resulting gene expression data using a number of
pathway analysis tools - Gene Set Enrichment Analysis
(GSEA) [33], Enrichment Map visualization [34], In-
genuity Pathway Analysis (IPA) and GeneMANIA. We
found new, non-previously described functional themes
and pathways, which may help elucidate the early and
late mechanisms of moxLDL-induced SMC phenotype
transformation and the onset and progression of athero-
genesis. While the in vitro atherogenesis model involving
moxLDL treatment of VSMC, particularly in the absence
of endothelial cells and immune and inflammatory cells,
is an oversimplified model of the complex process of
atherogenesis, our systems analysis on the interactions
of moxLDL and VSMC has uncovered several novel
gene and pathway changes. These observations now per-
mit hypotheses generation and in vivo functional testing
(such as gain and loss-of-function studies) to establish
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The microarray analysis of moxLDL treated cells has been
previously described [32]. Briefly, human coronary artery
SMCs were purchased from Clonetics (Walkersville, MD)
and cultured according to the manufacturer’s instructions
and used between passages 4–7. Confluent SMC cultures
were synchronized to quiescence by incubation for 48h in
basal medium (SmBM) containing 0.5% FBS. The cells
were then washed and incubated in SmBM+0.5% FBS in
the absence or presence of unoxidized LDL or moxLDL
(2 μg/ml) for 3h and 21h. The reactions were performed
in quadruplicates. DNA-free mRNA was extracted from
the cells and mRNA samples from corresponding cell cul-
tures were pooled to reduce inter-sample variation. Bioti-
nylated cRNA samples were hybridized to HG-U133A
oligonucleotide Gene Chip arrays (Affymetrix, Santa
Clara, CA). The data files from the arrays were analyzed
using Affymetrix GeneChipW Operating Software (GCOS)
version 1.0 (Affymetrix, Santa Clara, CA) to identify differ-
entially expressed genes.
Re-processing of gene expression data for Gene Set
Enrichment Analysis
The originally published set of differentially expressed
genes only contained those surpassing a threshold (at
least 2-fold differentially expressed), however GSEA
requires input of all genes ranked from most over-
expressed to most under-expressed. To gather this infor-
mation, we reprocessed the original Affymetrix HG-
U133A CEL image data files using the Affy library of the
Bioconductor package for the R programming language
[35]. Three arrays exist in this experiment: control, treat-
ment after 3h and treatment after 21h. Background cor-
rection and normalization was performed on the
datasets using the RMA method [36]. This data was then
reformatted for input into the GSEA software (GCT file
format).
Gene Set Enrichment Analysis (GSEA) based pathway
analysis
Pathway enrichment analysis was carried out by search-
ing for enriched gene-sets (e.g. pathways, molecular
functional categories, complexes) in the early time point
(3h) vs. control and the late time point (21h) vs. control
using GSEA. It was not possible to use a statistical test
to establish a gene ranking, as only gene expression data
from one pooled set of samples was available for each
experimental condition. Instead, a fold-change metric
was used, computed by GSEA, comparing moxLDL-3h
vs. Control and moxLDL-21h vs. Control. We used“gene set permutation” with 1000 permutations to com-
pute p-values for enriched gene-sets, followed by GSEA’s
standard multiple testing correction. We used GSEA’s
built- in gene identifier (ID) conversion system to con-
vert Affymetrix probeset IDs from the expression data
matrices to gene symbols for analysis. We used an
updated version (September 2, 2011) of a custom gene
set collection previously used for pathway analysis [37]
(http://baderlab.org/GeneSets). The collection comprises
Gene Ontology annotations [38], as well as pathways
from the HumanCyc [39], Kyoto Encyclopedia of Genes
and Genomes (KEGG) [40], MSigDB [33], NCI Nature
Pathway Interaction Database (PID) [41], NetPath [42]
and Reactome [43] databases.
Enrichment Map pathway analysis visualization
The resulting enrichment results were visualized with
the Enrichment Map plugin for the Cytoscape network
visualization and analysis software. We loaded GSEA
results using a p-value cut-off of 0.005 and a q-value
threshold of 0.1. In these maps, each gene set is symbo-
lized by a node in the network. Node size corresponds
to the number of genes comprising the gene-set. The en-
richment scores for the gene-set are represented by the
node’s color (red indicates up-regulation, blue represents
down-regulation). The color of the node center indicates
the enrichment score for the early time point (3h), and
the node border color indicates the score for the late
time point (21h). To intuitively identify redundancies be-
tween gene sets, the nodes are connected with edges if
their contents overlap by more than 50%. The thickness
of the edge corresponds to the size of the overlap. We
used version 1.2 of the Enrichment Map software in
Cytoscape 2.8.2.
GeneMANIA
GeneMANIA (http://www.genemania.org/) finds other
genes that are related to a set of input genes, using a
very large set of functional interaction data [44]. Inter-
action data include protein and genetic interactions,
pathways, co-expression, co-localization and protein do-
main similarity. We searched the GeneMANIA web site
using differentially expressed genes underlying specific
functional themes to find out how the genes interact
with each other. The resulting sub-network containing
our query genes and additional related genes helps inter-
pret the mechanistic details of the functional themes we
define.
Ingenuity pathway analysis
We also used the commercial software Ingenuity Path-
way analysis (IngenuityW Systems; IPA) (http://www.
ingenuity.com/) to identify enriched pathways and func-
tional themes, as reported previously [45]. In particular,
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least 2-fold differentially expressed, as reported in the
original publication [32] were uploaded into the applica-
tion as standard human gene symbols. Each gene identi-
fier was mapped to its corresponding gene object in the
Ingenuity Pathways Knowledge Base (IPKB). The IPKB,
containing a large network of curated molecular interac-
tions and pathways, was searched to find sub-networks
enriched in genes of interest. A total of 77 and 205 genes
were found to be network eligible for the 3h and 21h
moxLDL experiments, respectively. Graphical represen-
tations of these sub-networks, containing direct and in-
direct molecular relationships, were generated.
Results and discussion
Overview of the integrative pathway analysis
Our GSEA-based analysis was summarized with the
visualization of an enrichment map depicting a variety of
molecular processes, here termed “functional themes”
(Figure 1). These themes are listed in Additional file 1:
Table S1, with a brief summary of their expression be-
havior at both 3h and 21h time points, following
moxLDL treatment. We observed an up-regulation of
genes in functional themes related to proliferation, cell
migration, ECM production, cholesterol biosynthesis
and protein translation (Figure 1). These observations
are consistent with the hallmarks of SMC transform-
ation. The differential gene expression patterns for spe-
cific functional themes of interest, mostly non-reported
in the SMC transformation, are also shown as heat
maps. For instance, it is evident that the “endopepti-
dase inhibition” theme is significantly down-regulated
(Figure 1, Additional file 1: Table S1) and several mem-
bers of the Serpin family of protease inhibitors are sig-
nificantly down-regulated at 21h, as shown in the
associated heat map (Figure 2). This down-regulation
suggests increased proteolytic activity during SMC trans-
formation. To our knowledge, endopeptidase activity
has not been reported to play any role in SMC trans-
formation. Other heatmaps of interest are shown in
Additional file 2: Figure S1. In a complementary fashion,
the investigation of canonical pathways at 3h (Additional
file 3: Table S2) and 21h (Additional file 4: Table S3)
using IPA, revealed enrichment in specific signaling and
metabolic pathways. The 20 most significant ones were
selected for further study (Figures 3A and 3B, respect-
ively). Of note, JAK/STAT, Interleukin and IGF-1 signal-
ing pathways, were deregulated at both time points. The
dataset was further organized to predict how moxLDL
treatment on SMCs might influence the cross-talk
among interacting proteins. We identified eight major
networks involving differentially expressed genes (4 net-
works at 3h; 4 networks at 21h). Interestingly, certain
molecules in these networks (see below for details) werefound to nucleate clusters of protein-protein interactions
that may act as organizational “hubs” and additionally
verified certain functional themes of the GSEA-based
pathway analysis.
In-depth pathway analysis of specific molecular themes of
interest
Cholesterol biosynthesis
Since the molecular mechanisms for SMC phenotype
transformation during AT have not yet been clearly deli-
neated, we initially examined the cholesterol biosynthesis
theme (Figure 1) in SMC stimulated with moxLDL for
3h and 21h in detail (Figure 4A). Eight cholesterol
synthesis-related genes were up-regulated in 3h with
LDLR, IDI1, HMGCS1, INSIG1 moderately up-regulated
and HMGCR highly up-regulated. Seven genes were
down-regulated with INSIG2 and APOE being the most
strongly decreased ones (Figure 4B). A GeneMANIA
network analysis for interactions among the gene pro-
ducts suggested an initiation of cholesterologenesis with
HMG-CoA synthetase (HMGCS), conversion of acetyl-
CoA and acetoacetyl-CoA to 3-hydroxy-3-methylglu-
taryl- CoA (HMG-CoA) and subsequent HMG-CoA re-
ductase (HMGCR) catalysis of the rate-limiting step in
cholesterol biosynthesis by converting HMG-CoA to
mevalonate (Figure 4C). INSIG1 accelerates the degrad-
ation of HMGCR in the proteasome [46]. SCAP binds and
retains INSIG1 in the ER and the binding of INSIG1 to
SREBP1 and 2 facilitates SCAP-mediated transport of
SCAP-SREBP complexes to the Golgi complex for degrad-
ation [47]. In the presence of sterols, INSIG2 regulates
lipid synthesis by blocking the proteolytic activation of
SREBPs by SCAP [48]. The down-regulation of SCAP,
SREBF2 and INSIG2 and up-regulation of INSIG1,
HMGCS1 and HMGCR in moxLDL-SMC indicates the
initiation of cholesterol synthesis in the 3h moxLDL-SMC
cells.
Cholesterol metabolism genes in 21h moxLDL-SMC
were more robustly regulated with 26 genes up-regulated
and 7 genes down-regulated. The most highly upregulated
genes were G6PD, INSIG1, HMGCS1, FDPS and LSS and
the most strongly down-regulated genes were APOE,
LEPR, INSIG2, CYP51A1 and TNSF4 (Figure 4B). Gene-
MANIA network analysis indicated that genes encoding
enzymes essential for the sequential enzymatic conversion
of Acetyl-CoA and Acetoacetyl-CoA to cholesterol were
all up-regulated in moxLDL-SMC (Figure 4C). The ana-
lysis also showed multiple interactions among the
enzymes (including FDFT1, NSDHL, HSD17B7, LSS,
SOLE, SC5DL, SC4MOL and CYP51A1) involved in the
sequential conversion of farnesyl pyrophosphate to squa-
lene, oxidosqualene, lanosterol and finally cholesterol and
suggested that these enzymes are hub proteins or function
as a multi-subunit complex.
Figure 1 Enrichment map for moxLDL, p=0.005, q=0.1; Nodes represent gene sets that are enriched at the top or bottom of the
ranking of differentially expressed genes, as determined by GSEA, where the node size corresponds to number of genes in the set.
Edges indicate overlap between gene sets, where the thickness indicates the size of the overlap. Red indicates up-regulation, blue indicates
down-regulation. The centre of the nodes corresponds to the early time point (3h), whereas the border of the node corresponds to the late time
point (21h).
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most important sensor of sterol levels. At high choles-
terol levels, the complex is retained in the ER, but at
lower levels the SCAP-SREBP enters transport vesicles
[47]. In the Golgi, SREBP undergoes two steps of prote-
olysis, releasing a soluble transcription factor that regu-
lates many genes associated with cholesterol and lipid
metabolism. This leads to increased synthesis of choles-
terol and LDL receptors. A switch-like response thathelps to maintain cellular cholesterol in a narrow range
has been demonstrated in the ER. It is currently unclear
whether the sharp transition is due to cooperative
protein-protein interactions between SCAP molecules or
an abrupt change in the chemical activity of cholesterol
in the ER membrane when it crosses a threshold value
[49]. It has been proposed that the level of expression of
INSIG1 protein can influence the cholesterol-dependent
transition point, and reduction of cholesterol levels leads
Figure 2 ‘Endopeptidase Inhibition’ theme heatmap of representative SMC differential gene expression patterns induced by treatment
with moxLDL at 3h and 21 h.
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cells to cholesterol depletion [46]. In our study, INSIG-1
is highly expressed at 21h and thus we predict sustained
cholesterol synthesis would occur.
PDGF has been shown to regulate ABCA1 expression
in SMC [50]. However in our study, both ABCA1 and
ABCG1 were not expressed in moxLDL-treated SMC at
3h and 21h, in spite of an increased PDGF expression
and cholesterol biosynthesis. We propose that the lackof ABCA1 and ABCG1 in moxLDL-treated SMC, would
result in impaired cholesterol efflux leading to its accu-
mulation in SMCs during atherogenesis. This finding is
thus analogous to the observed down-regulation of
ABCA1 and ABCG1 transporters in lipid laden macro-
phages which results in a dysregulated reverse choles-
terol transport pathway that enhances lipid accumulation
and “foam cell” formation in moxLDL-treated macro-
phages [51-55].
Figure 3 Canonical Pathways from IPA. Bars correspond to the top 20 Canonical Pathways that surpassed the Ingenuity statistical threshold
(orange squares) using the Fisher’s exact test in the 3h (3A) and 21h (3B) moxLDL experiments, respectively.
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the enzyme responsible for esterifying excess cholesterol
for storage in lipid droplets [56]. Cholesterol ester stor-
age and accumulation as oil droplets in microsomes
occurs during cholesterologenesis and may contribute to
formation of fatty streaks. NAD(P)H dehydrogenase-like
protein (NSDHL), a C4 demethylase that is involved in
the removal of C-4 methyl groups from the cholesterol
precursor lanosterol, is localized to the surface of the
ER. It also accumulates on the surface of lipid droplets
that function as intracellular storage compartments for
neutral lipids and cholesterol esters and participates in
the regulation of cellular cholesterol content [57]. The
up-regulation of NSDHL in moxLDL-SMC may there-
fore play a role in the accumulation of cholesterol in
moxLDL-SMC.
Cholesterol metabolism was tightly regulated in 21h
moxLDL-SMC, judging by the differential regulation of
the network of LDLR, LDLRAP1, LIPA, RXRA, APOC3
and APOL2 genes (Figure 4C). LDLRAP1 is required for
internalization of the LDL-LDLR complex in endocytic
vesicles [58]. Lysosomal acid lipase (LIPA) has been
reported to play an important role in cellular metabol-
ism by releasing cholesterol, which in turn suppressesfurther cholesterol synthesis and stimulates esterification
of cholesterol within the cell. ApoE knock-out mice
spontaneously develop atherosclerosis. However, this ef-
fect is counteracted by the retinoid X receptor (RXRA)
in the same model [59]. APOC3 inhibits the catabolism
and hepatic uptake of apoB-containing lipoproteins and
enhances the catabolism of HDL particles, as well as the
adhesion of monocytes to vascular endothelial cells and
activates inflammatory signaling pathways [60]. The up-
regulation of APOC3 in moxLDL-SMC would inhibit
cholesterol clearance via HDL. Interestingly, the obser-
vations of up-regulation of LDLR, LDLRAP1, INSIG1,
SCAP, LIPA, RXRA, NSDHL, APOC3 and APOL2 and
the down-regulation of INSIG2 and APOE in moxLDL-
SMC further suggest a dysregulation of cholesterol me-
tabolism and clearance in moxLDL-SMC, a situation
that favors foam cell formation. APOL2 has not been
reported to be expressed in neointima or the media but
is up-regulated in HUVECs following prolonged stimula-
tion with TNF-α [61-63].
To date, statins are used therapeutically to inhibit de
novo hepatic cholesterol synthesis to lower the levels of
plasma LDL-cholesterol, the major risk factor for athero-
sclerosis and coronary heart disease. Inhibition of
INSIG2







































Figure 4 Cholesterol biosynthesis theme analysis. (A) Cholesterol biosynthesis theme from enrichment map. (B) Cholesterol biosynthesis-
associated heatmap. (C) Network of interactions among moxLDL-SMC cholesterol metabolism related genes, as retrieved by the GeneMANIA
website, colored by gene expression at 3h (node center) and 21h (node border). Red indicates up-regulation, blue indicates down-regulation and
white indicates no differential expression or no expression data available. Circles represent genes and connecting lines represent interactions
between genes. The network was generated using a GeneMANIA query of 43 cholesterol synthesis related genes (large circles) differentially
expressed at either 3h or 21h. GeneMANIA retrieved known and predicted interactions between these genes and added extra genes (smaller
white circles) that are strongly connected to query genes (we used the default setting of 20 additional connecting genes). Light blue lines
indicate pathway interactions from the Reactome pathway database, dark blue lines indicate experimentally determine physical interactions, from
various protein interaction databases included in GeneMANIA, and brown lines indicate predicted interactions, mostly from the I2D database of
protein interactions predicted from experimentally determined physical interactions in other species. GeneMANIA advanced settings were used to
search only physical, pathway and the default set of predicted networks. We excluded co-expression, co-localization and genetic interaction
networks from the search to focus the analysis on higher confidence physical and pathway interactions.
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results in an inhibition of the synthesis of several non-
sterols such as dolichols and ubiquinone and contributes
to the side effects observed in patients on statin therapy.
Consequently, attention has been directed towards
enzymes such as squalene synthetase, squalene epoxi-
dase and oxidosqualene cyclase, which are involved in
cholesterol synthesis beyond farnesyl pyrophosphate as
potential targets. Preclinical studies with oral bioavail-
able inhibitors have demonstrated the potential of squa-
lene epoxidase inhibitors as hypocholesterolemic agents,
however high circulating levels of squalene epoxidase
inhibitors are believed to be responsible for dermatitis
and neuropathy observed in the participants [64]. To the
best of our knowledge, the hypocholesterolemic effects
of inhibitors of the enzymes involved in post-squalene
cholesterol biosynthesis have not yet been reported.
These enzymes [including LSS, SC5DL, CYP51A1,
SC4MOL, NSDHL, HSD17B7 and C14orf1 (Figure 4C)]
exhibit extensive physical interactions with each other,
suggesting they may form a scaffold and act via a multi-
step multi-enzyme process. Inhibition of any one of the
enzymes may destabilize the complex and inhibit choles-
terol formation. They, thus, could be considered poten-
tial targets for the design of hypocholesterolemic drugs
for therapeutic intervention of SMC phenotype trans-
formation and atherogenesis.The significance of moxLDL-mediated induction of
cholesterol synthesis in SMC phenotype transformation
is believed to be related to the proinflammatory proper-
ties of atherogenic LDL particles. According to the
“oxidation hypothesis of atherogenesis”, specific proin-
flammatory oxidized phospholipids that result from the
oxidation of LDL phospholipids containing arachidonic
acid are largely generated by potent oxidants produced
by the lipoxygenase and myeloperoxidase pathways.
These so-called mildly or minimally oxidized LDL and
their active components, such as polyoxygenated choles-
teryl ester hydroperoxides, are recognized by the innate
immune system via Toll-like receptor (TLR) activation
(such as TLR4). This leads to the recruitment of spleen
tyrosine kinase (Syk), cytoskeletal rearrangements and
macropinocytosis which in hyperlipidemic environments
leads to excessive lipid accumulation in monocytes,
macrophages and SMC in vascular lesions, foam cell for-
mation, vascular inflammation and ultimately the develop-
ment of atherosclerotic plaques [65,66]. TLR engagement
stimulates multiple signaling pathways, including PI3-K/
Akt and p38/p42/p44 MAPKs, which activate transcrip-
tion factors (e.g. NFkB, IRFs, STAT1, STAT3, AP-1).
The activation of these pathways also activates the
expression of proinflammatory cytokines (e.g. IL1α
TGFβ, MCP-1, IFNγ) and growth factors (e.g. PDGF,
IGF, EGF, FGF) involved in mitogenesis of VSMCs
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that we have analyzed substantiate these observations
and suggest further details about the molecular
mechanisms of SMC phenotype transformation.
Inflammatory cytokines and growth factors
GSEA-based and IPA analysis found large clusters of
cytokines, including IL-1, IL-12, CSF-3, TGF-β, PDGF
and HGF, grouping many of the differentially expressed
genes of the dataset (Figure 1, Figure 5A). Other net-
works identified “hubs” belonging mainly to the IFN-α,
PDGF, NF-kB, VEGF and JAK/STAT signaling pathways
(Figure 5B). Such networks were also found in the 21h
treatment experiments, where members of the interleu-
kin family of proteins nucleated clusters of signaling
molecules regulating cell growth, proliferation and mi-
gration (Figure 5C). Cytokines and growth factors, in-
cluding Interleukins (IL-6, IL-1β), TGF-β, PDGF, HGF,
IGF-1 and members of the IFN family, have been shown
to activate signal transduction cascades that trigger re-
modeling of the cytoskeleton and change cell-to-matrix
adhesion [77]. Hepatocyte growth factor (HGF), previ-
ously linked to the regulation of cell motility and migra-
tion especially in cancer and atherosclerosis [78],
nucleated a network with members of the MAPK family.
In another network, IFN-γ was the major molecular
“hub” (Figure 5D). IFN-γ, known to be released at sites
of inflammation and in large amounts in the plaque,
induces vasodilation and synthesis of NO by SMCs,
which in turn contributes to hyperemia of inflammation.
IFN-γ-induced NO synthesis by SMCs may also be
involved in the regulation of vascular tone and prolifera-
tion of SMCs [79,80]. To the best of our knowledge, the
activation of IL12, IFN-α, HGF and VEGF signaling
pathways in SMC undergoing phenotype transformation
has not been reported. In a complementary fashion, ca-
nonical pathways belonging to these networks were also
enriched in our dataset, as seen in Figures 3A and 3B.
MicroRNAs (miRNAs) have recently been implicated in
the regulation of atherosclerosis and lipoprotein metabol-
ism, by affecting endothelial integrity, macrophage inflam-
matory response to atherogenic lipids, vascular smooth
muscle cell proliferation, and cholesterol synthesis [81].
We found that certain miRNAs (miR-203, miR-511, miR-
590-3p, miR-346*/miR-1207-5p/miR-4763-3p) serve as
organizational hubs of several signal transduction pathways
in one of our IPA networks (Figure 5D). Since miRNAs are
implicated in inflammatory processes that accompany
heart failure, AT, coronary artery disease, obesity and dia-
betes [82], we further investigated these pathways. Many of
the identified miRNAs, along with clusters of deregulated
proteins were, indeed, highly connected to the IFN-γ path-
way in the same molecular network (Figure 5D). Interest-
ingly the JAK/STAT, MAPK and IGF signaling pathways,which have been shown to play clearly defined roles in AT
pathogenesis [83-85], served as major intracellular media-
tors of the cytokine pathways in the generated molecular
networks. Recent integrative approaches demonstrating a
plethora of IFN-γ-regulated mRNAs and targeted mRNAs
[86], coupled with our observation of miRNAs in the IFN-
γ-dominated molecular network suggest that inflammatory
signaling may be regulated through non-classical miRNA-
related cytokine pathways, beyond the classical JAK/STAT
and MAPK pathways.
G-protein coupled receptors (GPCRs)
VSMC migration involves a dominant plasma membrane
leading lamellae, or leading edge, protruding from the
cell to make contact with an extracellular substrate.
Binding is accomplished via integrin transmembrane
receptors that enable the formation of focal complexes
and secure focal adhesions. An intracellular signal trans-
duction cascade, involving G-protein and tyrosine-
kinases, results in the alignment of actin filaments and a
myosin contraction within the leading edge. Focal adhe-
sions are subsequently disengaged over the remainder of
the cell surface, and contractile forces propel the cell
forward in the direction of the anchoring leading edge
[87-91]. Thus, VSMC migration is predominantly regu-
lated by two receptor-coupled systems, GTP-binding
protein (G-protein)-coupled and tyrosine kinase-coupled
proteins. Signal transduction pathways from these two
systems appear to intersect as signals are transmitted.
To-date the mechanism of action of GPCRs in SMC mi-
gration has not been well delineated. The differential ex-
pression of the member genes of the GPCR theme
(Figure 1, Figure 6A) is shown in the associated heat map
(Figure 6B). Many of these genes (e.g. GPR1, GPR64,
GPRC5A, and GPR171), expected to be involved in regu-
lating SMC transformation, are up-regulated, whereas
Frizzled6, Frizzled8, GPR176, GPR32, GPR25, and
GPR124 are down- regulated. Frizzled2 is down-regulated
at 3h but strongly up-regulated at 21h. The receptors
encoded by these genes are specific to different signaling
molecules. The fact that one group of receptors seems to
be produced increasingly at the expense of a second group
could indicate a shift of the cell’s responsiveness to differ-
ent sets of signals. The most strongly up- and down-
regulated genes in the GPCR functional theme encode
various chemokines (CCL19, CCL20, CXCL2, and
CXCL12). These observations suggest that GPCRs could
regulate cell migration and trafficking of immune cells as
well as VSMC early in the course of mox-LDL treatment
(~3h) and that their effects might not be retained at later
events (~21h) (Figure 1, Figure 6B, Table 1). Additionally,
an IPA network of particular interest for the 3h treatment
experiment is shown in Figure 6C, where GPCRs interact
indirectly with members of the MAPK signaling pathway,
Figure 5 Cytokine and growth factor theme analysis. IPA networks from 3h (A, B, D) and 21h (C) experiments, involving cytokines and
growth factors as molecular hubs. Genes/proteins are illustrated as nodes and molecular relationships as connecting lines between two nodes
(direct relationships as normal lines; indirect relationships as dashed lines). Molecular relationships are supported by at least one literature
reference, or by canonical information stored in the IPKB. Grey nodes represent genes of interest, while white nodes represent hubs that were
added by the IPA algorithm to connect a set of genes of interest.
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http://www.biomedcentral.com/1471-2261/13/4and thus may be regulating important biological processes,
such as cell growth and proliferation, migration and differ-
entiation. Moreover, the GPCR family also acts as an
organizational hub in the 21h experiment (Figure 6D),
during which the enrichment map shows a significantdown-regulation of the GPCR functional theme
(Figure 6A), as already described. IPA proposed that
GPCRs regulate important signaling pathways, several of
which are revealed in our molecular networks (Figure 6D):
For example, (a) Rac, is a member of the Rho family of
Figure 6 GPCR signaling theme analysis. (A) GPCR theme from enrichment map. (B) GPCR - associated heatmap. (C)GPCR-associated IPA
network (3h) (D) GPCR-associated IPA network (21h). For color coding interpretation, please refer to Figures 1 & 5.
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http://www.biomedcentral.com/1471-2261/13/4proteins. Rho kinases have been widely demonstrated to
be up-regulated in activated SMCs by inflammatory stim-
uli [90], (b) CXC-motif type chemokines, which regulate
chemotactic responses, may participate in the recruitment
of inflammatory cells to sites of atherosclerosis develop-
ment [92], (c) FAK, focal adhesion kinase, which is
involved in integrin-dependent cell-to-matrix adhesion
signaling, is important for migration in the extracellular
matrix [93], (d) members of the JAK/STAT pathway, suchas STAT5, are involved in SMCs activation in atheroscler-
osis [84] and (e) MMPs which are major extracellular pro-
teolysis enzymatic systems that modify ECM, have evident
roles during inflammatory and vascular diseases [94].
Our enrichment map provides information regarding
the activity status (up- or down-regulation) of GPCR sig-
naling pathways during SMC transformation, while In-
genuity identifies cross-talk of this pathway with other
pathways. Based on these observations, we speculate that
Table 1 Novel Findings of the Integrative Pathway Analysis of moxLDL-induced SMC Phenotype Transformation
Theme Novel Findings
Cholesterol synthesis & transport The observation of upregulated cholesterol biosynthesis coupled with a dysregulation of the reverse cholesterol
transport pathway in moxLDL-induced SMC may promote the accumulation of cholesterol and cholesterol
esters in the cells, and facilitate foam cell formation during atherogenesis
GPCR signaling Observed GPCR signaling may have a role in SMC transformation. GPCR signaling following activation via inflammatory
or other microenvironmental stimuli have been implicated in responses, such as change of cell-to-cell and cell-to-matrix
adhesion, matrix remodeling, cell proliferation, migration, and immune cell trafficking and regulation. The activation of
GPCR pathways may thus play a role in the initiation of SMC dedifferentiation and phenotype transformation.
Cytokine & growth factor Potential role for IL12, IFN-α, HGF, CSF3 and VEGF signaling in SMC phenotype transformation.
Cell cycle control Up-regulation of HBP1, a repressor of cyclin D1 and CDKN1B, suggests a negative feedback loop auto-triggered
by the up-regulation of the core cell cycle machinery during SMC phenotype transformation.
Cell differentiation The deregulation of the ID2 and ZEB1 regulators of differentiation during SMC phenotype transformation is
consistent with the onset of SMC de-differentiation.
miRNA & de-differentiation Potential role of miRNAs in the regulation of SMC phenotype transformation via interactions with the IFN-γ pathway.
Nexus genes in complex networks Several “nexus” genes, including the components of a multi-subunit complex involved in the terminal stages of
cholesterol synthesis, miRNAs (e.g. miR-203, miR-511, miR-590-3p, miR- 346*/miR-1207-5p/miR-4763-3p), members of
the GPCR family of proteins (e.g. GPR1, GPR64, GPRC5A,GPR171, GPR176, GPR32, GPR25, and GPR124) and signal
transduction pathways were observed. These genes may play important roles in VSMC phenotype transformation
and in the pathogenesis of AT and coronary artery disease and may provide novel targets for drug discovery.
The original microarray data analyzed here has been deposited in the Gene Expression Omnibus database (accession GSE36487), and is publicly available for the
first time with this paper.
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http://www.biomedcentral.com/1471-2261/13/4GPCR signaling plays a role in SMC transformation. GPCR
signaling may mediate the initiation of SMC dedifferenti-
ation following activation via inflammatory or other micro-
environmental stimuli. The activation of GPCR pathways
might be implicated in a large number of responses, such
as change of cell-to-cell/cell-to-matrix adhesion, prolifera-
tion, matrix remodeling, migration, and immune cell traf-
ficking and regulation. These traits are consistent with the
SMC transformation process. Once these processes have
been completed, GPCR signaling is down-regulated, by a
mechanism that is yet to be elucidated. The maintenance
of the activated SMC phenotype could be regulated by
other “maintenance pathways”, such as cytokine signaling
pathways, which are up-regulated throughout the course of
the disease. We believe that such maintenance pathways
exist, given previous literature [22] and new evidence from
our study that the migratory and proliferative phenotype in
SMCs is maintained throughout moxLDL treatment by the
strongly up-regulated cell cycle control machinery.
Members of the GPCR superfamily are known to medi-
ate G-protein-coupled, cAMP-mediated signal transduc-
tion mechanisms for the detection of chemostimuli in the
main olfactory epithelium and heterogeneous cells in
mammals [95,96]. Since the olfactory sensing pathway was
highly regulated in SMC exposed to moxLDL (Additional
file 2: Figure S1), we speculate that in addition to moxLDL
receptors, the GPCRs up-regulated in this process may
participate in sensing this atherogenic agent.
Cell adhesion
SMC migration and proliferation induced by moxLDL
contributes to the thickening of the intima in restenosis
and AT. This process may be regulated by cadherins.Cadherins are transmembrane proteins which form cell-
cell contacts. Studies by Uglow et al. (2003) [97] and
Dwivedi et al. (2009) [98] have shown that MMP9 and
-12-dependent shedding of the extracellular portion of
N-cadherin results in the disruption of N-cadherin cell-
cell contacts. This process was shown to be associated
with the release and translocation of beta-catenin to the
nucleus and the induction of beta-catenin-mediated
intracellular signaling. This signaling cascade results in
the expression of cyclin D1 and increased VSMC prolif-
eration mediated by PDGF-BB [99,100]. These observa-
tions prompted us to analyze the cell-cell junction
theme (Figure 7A). Significant alterations of the cell ad-
hesion programming are implied via multiple ways in
our analysis: (A) A cadherin expressional switch accom-
panies the SMC phenotypic transition; CDH10, CDH5
are up-regulated, while CDH19 and PCDH9 are down-
regulated 21h post-moxLDL treatment (Figure 7B). Cad-
herins belong to the adherens junction apparatus, medi-
ating cell-to-cell, homotypic cell adhesion coupling in
epithelial or even stromal cells [101]. It has been postu-
lated that molecular “switching” in these molecules con-
tributes to the turnover of cell adhesion properties of
the cells in various pathologies and participate in motile
phenotypes, as in the case of cancer metastasis or even
normal development [102-104]. (B) Cluster of differenti-
ation (CD) molecule expressional switching, accompan-
ies SMC transition; CD151 and CD9 are up-regulated,
whereas CD47 is down-regulated with moxLDL treat-
ment (Figure 7B). CD9 is a cell-surface glycoprotein
belonging to the tetraspanin family of proteins, believed
to be involved in complexes with integrins, thus mediat-
ing cell migration, adhesion and platelet aggregation
Figure 7 Cell adhesion theme analysis. (A) cell-to-cell junction theme from enrichment map. (B) Cell- to-cell junction-associated heatmap. For
color coding interpretation, please refer to Figure 1.
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http://www.biomedcentral.com/1471-2261/13/4[105]. CD151, belongs to the same family of proteins,
additionally shown to accelerate cancer metastasis, thus
promoting a migratory phenotype [106]. (C) Overexpres-
sion of PARD3 (Figure 7B), a member of the Par3/Par6
polarity complex, might suggest that SMC transition is
accompanied by a polarized migration [107]. Taken to-
gether, these observations point to altered cell-adhesion
machinery in the activated SMC that is consistent with a
migratory phenotype.Cell cycle control
The cell-cycle theme (Figure 8A) served as a proof-of-
concept in our analysis, since cell cycle control and cell
death machineries induce tremendous impact in tissue
homeostasis of the adult organism, with known roles in
inflammatory, vascular, neoplastic and neurodegenera-
tive diseases [108]. Since the activated SMC phenotype
is highly proliferative [4], disturbances in the cell-cycle
control machinery are expected. The theme was clearly
Figure 8 Cell-cycle control theme analysis. (A) Cell-cycle theme from enrichment map. (B) Cell-cycle- associated heatmap. (C) Cell-cycle-associated
IPA network (21h). For color coding interpretation, please refer to Figures 1 & 5.
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http://www.biomedcentral.com/1471-2261/13/4up-regulated in both time-points (Figure 8A, Table 1).
Details drawn from the associated heatmap (Figure 8B)
suggest that cyclin D1 is up-regulated and the cyclin-
dependent kinase (CDKN) inhibitor, CDKN2B, is down-
regulated, which is consistent with G1/S progression.
Interestingly, HBP1 which is known to repress cyclin D1
[109], as well as CDKN1B are up-regulated, suggesting
that a negative feedback loop to down-regulate cell
growth could be already initiated, most probably trig-
gered from the up-regulation of the core machinery. IPA
also verified the involvement of the cell cycle control
machinery in the 21h time point (Figure 8C). Specific-
ally, proteins in our dataset are clustered around the key
regulatory molecules of the cell cycle, such as the cyclin,
the CDK, and the Rb/E2F family members (Figure 8C).
Cell differentiation
An important aspect of SMC transition into a migratory
and proliferative phenotype is the loss of the differen-
tiated and quiescent phenotype. Regulatory factors of
cell differentiation most likely regulate this transition. In
one of our IPA networks (Figure 8C), we captured two
potential regulators of differentiation: (a) DNA-binding
protein inhibitor-2 (ID2), a transcriptional regulator
which inhibits the function of basic helix-loop-helix
transcription factors [110], and (b) Zinc-finger E-Box-
binding homeobox 1 (ZEB1), a transcription factor
involved in the generation of more mesenchymalFigure 9 Myogenic contraction-associated IPA network. For color codiphenotypes [29]. Interestingly, both ID2 and ZEB1 were
deregulated in our dataset. Although IL-1β-induced ID2
gene expression has been described in SMCs [111],
ZEB1 has not been reported to be involved in SMC
phenotype transformation.
Myogenic contraction mechanism
It has been reported that moxLDL induces a sustained
and intense calcium-dependent retraction of SMC by
down-regulation of the expression of genes responsible
for the synthesis of SMC contractile proteins such as α-
actin, smooth muscle myosin heavy chain-1, non-muscle
myosin and calponin, a thin filament protein involved in
the regulation of actin-myosin interactions [112].
moxLDL also stimulates collagen production, DNA syn-
thesis and SMC proliferation [112,113]. A subnetwork of
actin and actin-related gene/proteins was found in the
21h experiment (Figure 9). This network clusters mole-
cules, such as myosin, tropomyosin and cofilin around
actin filaments, involved in the myogenic contraction
mechanism. Interestingly, the enrichment map reveals a
large down-regulation of the theme “muscle function” in
the 21h experiment (Figure 1). These observations are in
concordance with cytoskeletal rearrangements, relevant
to transformation of SMCs into the migratory phenotype
[19].
** The novel findings in this paper are summarized in
Table I.ng interpretation, please refer to Figure 5.
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Pathway analysis of the transcriptomic data of the
in vitro model of moxLDL induced-VSMC phenotype
transformation using GSEA, Enrichment Map Cytoscape
plugin, GeneMANIA and IPA software identified several
pathways known or expected to be disturbed during
SMC transformation in addition to several novel regula-
tors that may play key roles in the onset and progression
of AT. The identification of these novel potential regula-
tory genes now permit hypothesis generation and in vivo
functional experimentation (such as gain and loss-of-
function studies) to establish causality with the process
of SMC phenotype transformation, AT and coronary ar-
tery disease and to possibly reveal novel diagnostic mar-
kers and targets for drug discovery.
Additional files
Additional file 1: Table S1. List of functional themes (Column A), taken
from the enrichment map (Figure 1), with their explained behavior,
according to the node colors, at 3h (column B) and 21h (Column C) time
points.
Additional file 2: Figure S1. Heat maps of SMC differential gene
expression patterns, induced by treatment with moxLDL at 3h and 21h.
Partial information from these heat maps was used to draw Figures 4, 6,
7 and 8.
Additional file 3: Table S2. IPA results. All the top-listed canonical
(metabolic & signaling) pathways using the Fisher’s exact test in the 3h
(Additional file 1: Table S1) and 21h (Additional file 2: Table S2) moxLDL
experiment, respectively. Column A depicts canonical pathway name as
tagged in the Ingenuity knowledgebase; column B depicts the Fisher
exact test –log(P-Value); column C depicts the statistical threshold;
column D provides the correspondence of the moxLDL differentially
expressed genes to each of the individual canonical pathways. Partial
information from these tables was plotted as Figures 3A and 3B in this
manuscript.
Additional file 4: Table S3. IPA results. All the top-listed canonical
(metabolic & signaling) pathways using the Fisher’s exact test in the 3h
(Additional file 1: Table S1) and 21h (Additional file 2: Table S2) moxLDL
experiment, respectively. Column A depicts canonical pathway name as
tagged in the Ingenuity knowledgebase; column B depicts the Fisher
exact test –log(P-Value); column C depicts the statistical threshold;
column D provides the correspondence of the moxLDL differentially
expressed genes to each of the individual canonical pathways. Partial
information from these tables was plotted as Figures 3A and 3B in this
manuscript.
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